Figure 6.

Trametinib treatment of established pancreatitis leads to reverse of tissue damage but not of tissue mass. CP protocol with inhibitor or vehicle treatment (A) or pancreatitis with recovery protocol (B). (C) Immunoblot for levels of phosphorylated MAPK, total MAPK, and the loading control β-actin. The ratio of the band intensities of phosphorylated/total MAPK is indicated under each lane. (D) Histologic representation of tissue remodeling and immune cell counts with quantitation (E and F, respectively), n ≥ 3 in all groups. White bars indicate the recovered cohort, green bars indicate cerulein + vehicle treated, and yellow bars indicate the cerulein + trametinib treated group. (G) Relative pancreas mass, defined by percentage pancreas weight over body weight, of each treatment group, n = 4 in all groups. (H) qRT-PCR analysis of acinar markers Amy2b, Ptf1a, and Mist1 and ductal marker Krt19, n = 3.